Clinical Trial Results: Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression [Phase 4]

View source ↗

Summary

Phase 4 trial assessing DNA testing to guide transition of kidney transplant recipients to belatacept-only immunosuppression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Transplant Failure Complications

Drugs mentioned

• belatacept (belatacept)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Kidney Transplant Immunosuppression | Phase 4 | Status: COMPLETED | Results posted: 2026-08-14